Akito Yasuhara

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 2007-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akito Yasuhara. Retrieved from https://idiyas.com/inventor/akito-yasuhara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Tokyo, JP (2007 - 2013)
Toshima-ku, JP (2011 - 2014)

Company Filing History:

10 out of 314

Taisho Pharmaceutical Co., Ltd.

patents

Years Active: 2007-2014

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8729271 - Glycine transporter inhibiting substances (2014-05-20),

2. 8642626 - Ethinyl-pyrazole derivative (2014-02-04),

3. 8623898 - Glycine transporter inhibiting substances (2014-01-07),

4. 8350060 - 2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative (2013-01-08),

5. 8258133 - 2-amino-bicyclo[3.1.0]hexane-2, 6-dicarboxylic ester derivative (2012-09-04),

6. 8076502 - 2-amino-bicyclo(3.1.0) hexane-2,6-dicarboxylic ester derivative (2011-12-13),

7. 8039647 - 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative (2011-10-18),

8. 7960579 - 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative (2011-06-14),

9. 7381746 - 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative (2008-06-03),

10. 7157594 - 6-Fluorobicyclo[3.1.0]hexane derivatives (2007-01-02),

Title: **Akito Yasuhara: Innovating the Future of Pharmacology**

Introduction

Akito Yasuhara, a prominent inventor based in Tokyo, Japan, has made significant contributions to the field of pharmacology with a remarkable portfolio of 10 patents. His innovative work mainly focuses on developing novel compounds that target various neurological and psychiatric conditions, showcasing his dedication to improving therapeutic options for patients worldwide.

Latest Patents

Among his most recent patents are pioneering inventions that address critical mental health challenges. One notable patent is for glycine transporter-inhibiting substances, which aim to provide novel compounds effective in preventing or treating diseases such as schizophrenia, Alzheimer's disease, cognitive dysfunction, and anxiety disorders, including generalized anxiety disorder, panic disorder, and post-traumatic stress disorder. Another significant contribution is the ethinyl-pyrazole derivative, which presents a novel compound exhibiting antagonistic activity against group II metabolism-type glutamic acid receptors. This invention holds promise as a therapeutic agent for mood disorders, anxiety disorders, and other neurological challenges, including drug dependence and sleep disorders.

Career Highlights

Akito Yasuhara has been associated with esteemed companies like Taisho Pharmaceutical Co., Ltd., where he has been instrumental in the research and development of new therapeutic compounds. His innovative mindset and dedication to addressing pressing health issues have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Throughout his career, Yasuhara has collaborated with notable peers, including Kazunari Sakagami and Hiroshi Ohta. These collaborations have fostered a synergistic approach to research, enhancing the efficacy and scope of their work in developing cutting-edge therapeutic solutions.

Conclusion

Akito Yasuhara continues to be a driving force in the field of pharmacology, with his extensive patent portfolio highlighting his innovative spirit and commitment to enhancing patient care. His work not only contributes to the scientific community but also has the potential to transform lives through improved treatment options.

Profile summary based on public USPTO records.